An observational study in Shock, Cardiogenic, Cardiac Arrest and Extracorporeal Circulation; Complications, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-04.
Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Shock, Cardiogenic with a site in China — 18 open to participants now, 18 under way, none of them phase 3. Shock, Cardiogenic · China.
Among the 20 studies in Shock, Cardiogenic with a site in China, this one is one of 3 that started in 2023, is one of 6 observational ones, reaches primary completion later than 2 of the 17 other live ones, and was the 10th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →18 of the 20 studies in Shock, Cardiogenic with a site in China are open now. Recruiting first, the newest first:
ForQaly Medical (Shanghai) Co., Ltd · Sites in China
Ages 18–80
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Renmin Hospital of Wuhan University · Sites in China
Ages 18+
Xiaotong Hou · Sites in China
Ages 18+
Shenzhen Core Medical Technology CO.,LTD. · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 136 is below the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Median enrollment 82 across the 14 interventional studies, 517 across the 6 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 20 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 318 studies on the registry; 91 are open to participants now.
First Affiliated Hospital Xi'an Jiaotong University has 1 study filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
3 of the studies in Shock, Cardiogenic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06862700Xiaotong HouEffect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients | 2027-01-01 |
| NCT07380659Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySafety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock | 2027-01-30 |
| NCT07560085ForQaly Medical (Shanghai) Co., LtdCatheter-Oriented Unloading and Recovery With a Left Ventricular Assist Gear: Efficacy in Post Cardiotomy Cardiogenic Shock | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Shock, Cardiogenic with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to monitor hemodynamic differences between central veno-arterial extracorporeal membrane oxygenation (VA ECMO) and peripheral VA ECMO. The main question it aims to answer is:
Participants require VA ECMO support, will be divided into two groups in an intention-to-treat analysis: central artery cannulation and peripheral artery cannulation.
Researchers will analyze different cannulation strategies for VA-ECMO and identify potential advantages and disadvantages for two groups of VA-ECMO.
Participants require VA ECMO support for cardiogenic shock or cardiac arrest.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Femoral artery cannulation for veno-arterial extracorporeal membraneous oxygenation (VA ECMO)
Procedure: Veno-arterial extracorporeal membrane oxygenation
Axillary artery cannulation for veno-arterial extracorporeal membraneous oxygenation (VA ECMO)
Procedure: Veno-arterial extracorporeal membrane oxygenation
Veno-arterial extracorporeal membrane oxygenation (VA ECMO) is mainly used for circulatory support in patients with severe cardiopulmonary failure. VA ECMO drains the blood from the venous system followed pumping the blood back into the arterial vascular compartment after oxygenation. It can be divided into two cannulation strategies for VA ECMO support, namely peripheral VA ECMO and central VA ECMO based on the arterial cannulation site. Peripheral VA ECMO is established via the femoral artery (FA), whereas axillary artery (AX) is an arterial cannulation site in central VA-ECMO.
Oxygen saturation-no. (%)
Blood gas analysis
Time frame: Through VA ECMO support completion, an average of 1 week
Left ventricular end-diastolic volume (ml)
echocardiography
Time frame: Through VA ECMO support completion, an average of 1 week
Left ventricular End-systolic volume (ml)
echocardiography
Time frame: Through VA ECMO support completion, an average of 1 week
Stroke volume (ml)
echocardiography
Time frame: Through VA ECMO support completion, an average of 1 week
Mitral valve area(cm2)
echocardiography
Time frame: Through VA ECMO support completion, an average of 1 week
Rate of successful weaning from VA ECMO
Weaning success is defined as survival after complete removal of the extracorporeal circuit without requirement for further mechanical support or heart transplant.
Time frame: Through study completion, up to 2 years
VA ECMO duration
Length of VA ECMO support
Time frame: Through VA ECMO support, an average of 1 week
Cannulation-related complications
Cannulation-related complications include bleeding, limb ischemia, revision of cannulation site, wound complications. Limb ischemia is defined as ischemia requiring any surgical procedure, including revision of the arterial/distal perfusion cannula, fasciotomy for compartment syndrome, gangrene, or amputation. Wound complication is defined as infection or requirement of an additional surgical intervention, such as arterial repair, washout with or without vacuum-assisted closure, and muscle flap closure.
Time frame: Through study completion, up to 2 years
Duration of ICU stay
Intensive care unit length of stay
Time frame: Through study completion, up to 2 years
Duration of hospital stay
Length of hospital stay
Time frame: Through study completion, up to 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Oct 2024, 14 months after the start.
Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 14 months is below that.
Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital Xi'an Jiaotong University →